Clinical trial · Interventional
T900607 in Treating Patients With Gastroesophageal Junction Cancer
A Phase II Study Of Intravenous T900607-Sodium In Subjects With Previously Treated Gastric Carcinoma
NCT00054249CI-TRIAL-00011389completedPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
RATIONALE: Drugs used in chemotherapy work in different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of T900607 in treating patients who have gastroesophageal junction cancer.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Gastric Cancer | Malignant Gastric Neoplasm | CURATED_BROADER | 0.80 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| T900607 | Drug | — | UNRESOLVED |
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
DISEASE CHARACTERISTICS: * Histologically or cytologically confirmed gastric or gastroesophageal junction carcinoma (gastric carcinoma closed to accrual as of 02/04) * Must have received 1 or 2 prior chemotherapy regimens for gastric carcinoma (gastric carcinoma closed to accrual as of 02/04) * Bidimensionally measurable disease * At least 1 lesion that is at least 10 mm by CT scan * No CNS metastases or carcinomatous meningitis PATIENT CHARACTERISTICS: Age * 18 and over Performance status * Karnofsky 70-100% Life expectancy * At least 12 weeks Hematopoietic * Absolute neutrophil count ≥ 1,500/mm\^3\* * Platelet count ≥ 100,000/mm\^3\* * Hemoglobin ≥ 8.5 g/dL\* NOTE: \*Independent of growth factor or transfusion support Hepatic * Bilirubin ≤ 1.5 times upper limit of normal (ULN) * AST and ALT ≤ 3 times ULN * INR ≤ 1.5 (unless receiving anticoagulants) * Albumin \> 2.5 g/dL Renal * Creatinine ≤ 2 times ULN Cardiovascular * No New York Heart Association class III or IV heart disease * LVEF ≥ 50% * No acute anginal symptoms Other * Not pregnant or nursing * Negative pregnancy test * Fertile patients must use effective contraception during and for 3 months after study participation * Able to comply with study procedures and follow-up * No other malignancy within the past 5 years except adequately treated basal cell or squamous cell skin cancer or carcinoma in situ of the cervix * No severe infection * No other concurrent severe medical condition or comorbidity that would preclude study participation PRIOR CONCURRENT THERAPY: Biologic therapy * More than 7 days since prior growth factors or blood transfusions * No concurrent therapeutic biological response modifier therapy * No concurrent immunotherapy Chemotherapy * See Disease Characteristics * No other concurrent cytotoxic chemotherapy Endocrine therapy * No concurrent hormonal therapy Radiotherapy * No concurrent radiotherapy (including palliative radiotherapy) Surgery * More than 4 weeks since prior major surgery Other * More than 4 weeks since prior investigational agents * No other concurrent investigational anticancer therapy
References
Publications (0)
Data not yet available
No reference posted for this study.